Neurological Biomarkers Market Size, Share, Growth, and Industry Analysis, By Type (Metabolomic,Genomic,Proteomic,Imaging,Others), By Application (Research Organizations,Hospital Laboratories,Independent Clinical Diagnostic Centers,Others), Regional Insights and Forecast to 2035

Neurological Biomarkers Market Overview

The global Neurological Biomarkers Market size is projected to grow from USD 9953.97 million in 2026 to USD 10823.95 million in 2027, reaching USD 21154.3 million by 2035, expanding at a CAGR of 8.74% during the forecast period.

The global neurological biomarkers market in 2024 was valued at approximately USD 10.0 billion and is projected to surpass USD 25.1 billion by 2033. In 2024, North America held over 41.6% share of the global neurological biomarkers market. The proteomic biomarkers type segment accounted for around 30.49% of the market in 2024. By application, Alzheimer’s disease segment held the largest share of 34.80% in 2024. Research organizations end‐user segment represented around 45.0% share of the end‐use market in 2024. Neurological Biomarkers Market size was calculated at about USD 9.14 billion in 2024 in some forecasts. Another source estimates USD 9.5 billion for 2024. 

In the United States, the neurological biomarkers market reached approximately USD 2.5 billion in 2024. U.S. accounted for about 91.00% of North America’s share in the neurological biomarkers market in 2024. Alzheimer’s disease application was the largest contributor in 2024 within U.S. segment. The U.S. neurological biomarkers market size is expected to grow markedly by 2033, with estimates projecting over USD 7.3 billion by then. Hospital laboratories in the U.S. are major end users. Proteomic biomarkers held about 30% share within U.S. type segments in 2024.

Key Findings

• Key Market Driver: Alzheimer’s disease segment contributed about 34.80% of application share in 2024 in global Neurological Biomarkers Market.
• Major Market Restraint:  Research organizations and others end‐use segment held about 45.0% share in 2024, implying constraints in clinical diagnostics uptake (~55.0%) due to infrastructure gaps.
• Emerging Trends:  Imaging biomarkers type segment was projected at around 29.5% share in 2025 in Neurological Biomarkers Market.
• Regional Leadership: North America held over 41.6% share of global market in 2024.
• Competitive Landscape: Proteomic biomarkers type segment had about 30.49% share in 2024 in global market; Alzheimer’s disease dominated application segment at ~34.80% share.
• Market Segmentation: By application Alzheimer’s disease around 35.0% of application share in 2025; by type imaging biomarkers ~29.5% in 2025.
• Recent Development:  Hospital labs segment is estimated to lead end‐user share with about 36% in 2025.

Neurological Biomarkers Market Latest Trends

The Neurological Biomarkers Market is seeing imaging biomarkers type segment gaining strong momentum, representing about 29.5% of market share in 2025. Alzheimer’s disease continues to dominate application share, with estimates placing it at 35.0% of application share in 2025, leading all diseases in terms of diagnostic activity. Proteomic biomarkers held roughly 30.49% share in 2024 globally, reflecting strong traction of proteins like β‐amyloid, p‑Tau, neurofilament light chain (NfL). The research organizations end‑user segment held about 45.0% share in 2024 globally, showing that R&D is central. In terms of type segmentation, imaging, proteomic, genomic, metabolomic each are gathering share, but imaging and proteomic lead. U.S market contributes about 91.0% of North America region share in 2024. Hospital laboratories end‑use expected to have ~36% share in 2025. Independent clinical diagnostic centers and hospital labs are increasing deployment of less invasive biomarkers, especially blood‐based assays with proteomic markers (~30%) over traditional CSF tests.

Neurological Biomarkers Market Dynamics

DRIVER

"Rising demand for early diagnosis of neurodegenerative diseases"

" "In multiple reports, Alzheimer’s disease application segment held ~34.80% share of applications in 2024. Prevalence of Alzheimer’s in the USA is about 6.7 million people in 2024, expected to more than double by 2060 to 13.8 million, driving demand for biomarkers. Total market global valuation around USD 9.14‑10.0 billion in 2024, with large share held by imaging and proteomic biomarkers (~30% each). Blood‐based biomarker launches (e.g. pTau217, NfL) have increased diagnostic accessibility. U.S. market is about USD 2.5 billion in 2024, with Alzheimer’s applications contributing significantly. 

RESTRAINT

"Limited availability and high cost of advanced diagnostic infrastructure"

Despite heavy R&D, hospital laboratories segment holds around 36% share in 2025 for end‐use, but independent clinical diagnostics and smaller hospitals lag. Proteomic biomarkers (~30.49%) require sophisticated equipment like LC‑MS/MS and immunoassays. Imaging biomarkers (~29.5% share in 2025) depend on expensive PET, MRI, CT machines, AI/ML enhanced image analysis. In many Asia‑Pacific or Middle East & Africa regions, infrastructure for imaging biomarkers is limited; this reduces penetration. Regulatory approvals and access to reimbursements are inconsistent — obstacles reflected in U.S. being ~91.0% of North America share and other countries much less.

OPPORTUNITY

"Growth in blood‑based and digital biomarkers to reduce invasiveness and costs"

 Proteomic biomarkers (~30.49% in 2024) include blood‑based assays such as β‑amyloid, p‑Tau, NfL. Digital biomarkers rising in interest. Imaging biomarkers share (~29.5%) high, but shifting to less expensive and more accessible proteomic and genomic solutions can expand in underserved regions. U.S. market already pushing blood‑based biomarkers. Research organizations (≈45.0% end‑user share in 2024) are funding innovations. Independent clinical diagnostic centers and hospital laboratories can adopt such biomarkers to tap markets; increased prevalence (e.g. Parkinson’s 1 million persons in U.S. in 2024) supports opportunity.

CHALLENGE

"Regulatory, validation, and standardization barriers"

Even though Alzheimer’s disease application holds ~35.0% share and proteomic/imaging types dominate, many biomarkers lack full regulatory approval or validation in large cohorts. Clinical diagnostic centers are slower to adopt; hospital laboratories (~36% share) are constrained by validation requirements. Genomic biomarkers (~35% in some reports) require large sample sizes and reproducibility; application in diseases such as Parkinson’s, multiple sclerosis lag behind Alzheimer’s. Ensuring consistent standards across U.S., Europe, Asia is challenging; disease prevalence data shows Parkinson’s ≈1 million in U.S. in 2024 advancing to ~1.2 million by 2030, but diagnostic rates remain low.

Neurological Biomarkers Market Segmentation

The Neurological Biomarkers Market is segmented by Type (Genomic, Proteomic, Metabolomic, Imaging, Others) and by Application (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorder, Others). Types such as imaging biomarkers represent roughly 29.5% share in 2025, proteomic biomarkers ~30.49% in 2024, genomic biomarkers in some studies commanding about 35% share in 2024 in type segmentation. Application segmentation: Alzheimer’s disease holds ~34.80‑35.0% of application share, Parkinson’s and multiple sclerosis smaller but growing.

BY TYPE

Metabolomic Biomarkers Application: Metabolomic biomarkers are extensively applied in the detection and monitoring of metabolic changes associated with neurological disorders. In Alzheimer's disease, metabolomic biomarkers are instrumental in identifying abnormalities in lipid metabolism and energy pathways, contributing approximately 12% to the metabolomic biomarker applications. Parkinson’s disease applications account for nearly 15%, focusing on detecting altered metabolites linked to dopaminergic neuron degeneration. Multiple sclerosis (MS) applications represent about 10%, where metabolomic profiling assists in recognizing inflammatory and immune-related metabolic disruptions. Emerging neurological conditions like autism spectrum disorder (ASD) account for roughly 7% of metabolomic biomarker applications, emphasizing amino acid and neurotransmitter metabolism abnormalities. The remaining 56% covers other neurological conditions such as traumatic brain injury and amyotrophic lateral sclerosis (ALS), highlighting the broad utility of metabolomic biomarkers.

The metabolomic application segment is sized at USD 2,040.0 million in 2025, capturing ~ 22.3% share, with a projected CAGR of 8.5 % through 2034.

Top 5 Major Dominant Countries in Metabolomic Application

• United States: Market size ~ USD 520.0 million, share ~ 25.5 %, CAGR ~ 8.6 %
• Germany: Market size ~ USD 230.0 million, share ~ 11.3 %, CAGR ~ 8.4 %
• United Kingdom: Market size ~ USD 220.0 million, share ~ 10.8 %, CAGR ~ 8.7 %
• Japan: Market size ~ USD 210.0 million, share ~ 10.3 %, CAGR ~ 8.3 %
• China: Market size ~ USD 200.0 million, share ~ 9.8 %, CAGR ~ 9.0 %

Genomic Biomarkers Application: Genomic biomarkers dominate in genetic profiling and risk assessment for neurological diseases. Alzheimer’s disease leads the genomic application segment with an estimated 33% share, focusing on gene mutations such as APOE variants. Parkinson’s disease follows closely, representing about 22%, with emphasis on mutations in genes like LRRK2 and SNCA. Multiple sclerosis accounts for around 16%, investigating immune-related genes like HLA-DRB1. Autism spectrum disorder contributes approximately 14% of genomic biomarker applications, highlighting rare genetic variants and copy number variations. Other hereditary neurological disorders and diseases, including Huntington’s disease and ALS, comprise the remaining 15%, showcasing the extensive scope of genomic biomarkers in neurological research and diagnosis.

The genomic application is estimated at USD 1,370.0 million in 2025, or ~ 15.0% share, and anticipated to grow at CAGR of 8.9 % over the forecast period.

Top 5 Major Dominant Countries in Genomic Application

• United States: Market size ~ USD 350.0 million, share ~ 25.6 %, CAGR ~ 8.8 %
• China: Market size ~ USD 180.0 million, share ~ 13.1 %, CAGR ~ 9.4 %
• Germany: Market size ~ USD 160.0 million, share ~ 11.7 %, CAGR ~ 8.9 %
• United Kingdom: Market size ~ USD 145.0 million, share ~ 10.6 %, CAGR ~ 9.0 %
• Japan: Market size ~ USD 145.0 million, share ~ 10.6 %, CAGR ~ 8.5 %

Proteomic Biomarkers Application: Proteomic biomarkers are critical in identifying protein alterations related to neurodegeneration. Alzheimer’s disease constitutes the largest portion, with about 42% of proteomic biomarker applications, focusing on proteins such as β-amyloid, tau, and neurofilament light chain (NfL). Parkinson’s disease accounts for 23%, primarily involving α-synuclein and DJ-1 protein markers. Multiple sclerosis applications represent roughly 13%, where inflammatory proteins are monitored. Proteomic studies in autism spectrum disorder remain emergent, covering around 6%, investigating synaptic and immune-related proteins. The remaining 16% includes applications in ALS and traumatic brain injury, underscoring the expanding role of proteomics in neurological diagnostics.

Proteomic application is pegged at USD 2,295.0 million in 2025, representing ~ 25.1% share, and forecast to grow at CAGR of 8.7 % through 2034.

Top 5 Major Dominant Countries in Proteomic Application

• United States: Market size ~ USD 580.0 million, share ~ 25.3 %, CAGR ~ 8.8 %
• Germany: Market size ~ USD 260.0 million, share ~ 11.3 %, CAGR ~ 8.7 %
• United Kingdom: Market size ~ USD 240.0 million, share ~ 10.5 %, CAGR ~ 8.9 %
• Japan: Market size ~ USD 225.0 million, share ~ 9.8 %, CAGR ~ 8.5 %
• China: Market size ~ USD 210.0 million, share ~ 9.2 %, CAGR ~ 9.1 %

Imaging Biomarkers Application: Imaging biomarkers hold a vital role in neurological disorder diagnosis and progression tracking. Alzheimer’s disease dominates this segment with approximately 48% share, utilizing advanced techniques such as amyloid PET, Tau PET, and MRI volumetric analysis. Parkinson’s disease comprises around 24%, leveraging modalities like DaTscan SPECT and PET imaging. Multiple sclerosis accounts for 17%, primarily driven by MRI-based lesion detection and brain atrophy assessment. Autism spectrum disorder imaging studies represent about 6%, involving functional and structural MRI. Other neurological conditions such as traumatic brain injury and Huntington’s disease contribute the remaining 5%, highlighting ongoing developments in imaging biomarkers.

The imaging application is sized at USD 1,370.0 million in 2025, ~ 15.0% share, with a forecast CAGR of 8.6 % through 2034.

Top 5 Major Dominant Countries in Imaging Application

• United States: Market size ~ USD 350.0 million, share ~ 25.6 %, CAGR ~ 8.7 %
• Germany: Market size ~ USD 155.0 million, share ~ 11.3 %, CAGR ~ 8.5 %
• Japan: Market size ~ USD 150.0 million, share ~ 10.9 %, CAGR ~ 8.4 %
• United Kingdom: Market size ~ USD 145.0 million, share ~ 10.6 %, CAGR ~ 8.8 %
• China: Market size ~ USD 140.0 million, share ~ 10.2 %, CAGR ~ 9.0 %

Other Biomarkers Application: The ‘Others’ category encompasses digital biomarkers, electrophysiological measures, and emerging technologies vital for neurological assessment. Alzheimer’s disease accounts for approximately 32% of this segment, utilizing digital cognitive assessments and EEG-based electrophysiology. Parkinson’s disease contributes around 25%, integrating wearable sensor data and digital gait analysis for disease monitoring. Multiple sclerosis applications cover about 16%, with electrophysiological markers such as evoked potentials being predominant. Autism spectrum disorder occupies roughly 11%, focusing on digital behavioral assessments and emerging diagnostic tools. The remaining 16% includes applications across other neurological disorders, reflecting the diverse innovation landscape in biomarker development.

The “Others” application segment is estimated at USD 1,778.0 million in 2025, accounting for ~ 19.4% share, and projected to expand at a CAGR of 8.8 % through 2034.

Top 5 Major Dominant Countries in Others Application

• United States: Market size ~ USD 460.0 million, share ~ 25.9 %, CAGR ~ 8.9 %
• China: Market size ~ USD 220.0 million, share ~ 12.4 %, CAGR ~ 9.3 %
• Germany: Market size ~ USD 190.0 million, share ~ 10.7 %, CAGR ~ 8.8 %
• United Kingdom: Market size ~ USD 180.0 million, share ~ 10.1 %, CAGR ~ 8.8 %
• Japan: Market size ~ USD 165.0 million, share ~ 9.3 %, CAGR ~ 8.6 %

BY APPLICATION

Research Organizations: This refers to academic, public, private research bodies using types of biomarkers (genomic, proteomic, imaging). In 2024, proteomic biomarkers (~30.49%) and imaging (~29.5%) are widely used in research settings. Research organizations end‑user share about 45.0% in 2024 globally, reflecting types being used for discovery and validation. Genomic biomarkers (~35%) adopted for studies of mutations, SNPs; metabolomic and others smaller shares (~<20–25%) in most reports.

Research organizations accounted for an estimated USD 1,640.7 million in 2025, representing about 17.9% share, and are expected to grow at a CAGR of 9.0% through 2034.

Top 5 Major Dominant Countries in the Research Organizations Segment

• United States: Market size ~ USD 395.0 million, share ~ 24.1 %, CAGR ~ 8.8 % in this segment
• Germany: Market size ~ USD 210.0 million, share ~ 12.8 %, CAGR ~ 9.3 %
• United Kingdom: Market size ~ USD 185.0 million, share ~ 11.3 %, CAGR ~ 9.1 %
• Japan: Market size ~ USD 155.0 million, share ~ 9.4 %, CAGR ~ 8.7 %
• China: Market size ~ USD 145.7 million, share ~ 8.9 %, CAGR ~ 9.2 %

Hospital Laboratories: Hospitals and hospital laboratories deploy types including proteomic, imaging, genomic; proteomic biomarkers in blood or CSF are used in hospital settings for Alzheimer’s diagnosis and monitoring; imaging biomarkers deployed via MRI/PET for structural and functional imaging. Hospital labs segment estimated to lead end‐use share at ~36% in 2025; imaging biomarkers requiring expensive imaging hardware; proteomic biomarkers more deployable.

Hospital laboratories held an estimated USD 2,290.0 million in 2025, or roughly 25.0% share, and are forecast to expand at about 8.6% CAGR through 2034.

Top 5 Major Dominant Countries in the Hospital Laboratories Segment

• United States: Market size ~ USD 600.0 million, share ~ 26.2 %, CAGR ~ 8.5 %
• Germany: Market size ~ USD 285.0 million, share ~ 12.4 %, CAGR ~ 8.8 %
• Japan: Market size ~ USD 250.0 million, share ~ 10.9 %, CAGR ~ 8.3 %
• France: Market size ~ USD 200.0 million, share ~ 8.7 %, CAGR ~ 8.7 %
• China: Market size ~ USD 180.0 million, share ~ 7.9 %, CAGR ~ 9.0 %

Independent Clinical Diagnostic Centers: These centers use mostly less complex types: proteomic and genomic biomarkers detectable via blood or saliva; imaging biomarkers less common unless centers are large. Their market share is less clearly quantified but smaller than hospital labs. The diagnostic centers are constrained by certification and reimbursement.

Independent clinical diagnostic centers contributed approximately USD 2,290.9 million in 2025, or ~ 25.0% share, and are projected to grow at a CAGR of 8.5 % until 2034.

Top 5 Major Dominant Countries in the Independent Clinical Diagnostic Centers Segment

• United States: Market size ~ USD 590.0 million, share ~ 25.8 %, CAGR ~ 8.6 %
• Germany: Market size ~ USD 270.0 million, share ~ 11.8 %, CAGR ~ 8.9 %
• United Kingdom: Market size ~ USD 225.0 million, share ~ 9.8 %, CAGR ~ 8.7 %
• China: Market size ~ USD 200.0 million, share ~ 8.7 %, CAGR ~ 9.3 %
• Japan: Market size ~ USD 195.9 million, share ~ 8.5 %, CAGR ~ 8.4 %

Others: Includes home diagnostics, digital biomarker providers, telemedicine, hybrid labs. These use digital, metabolomic, and emerging types. Their share is growing but in 2024 reports they account for remaining portion after research orgs (~45%), hospital labs (~36%), diagnostic centers, others.

The “Others” category (e.g. academic consortia, governmental labs) is estimated at USD 2,932.3 million in 2025, equating to ~ 32.0% share, with a projected CAGR of 8.9 % through 2034.

Top 5 Major Dominant Countries in the Others Segment

• United States: Market size ~ USD 750.0 million, share ~ 25.6 %, CAGR ~ 8.7 %
• China: Market size ~ USD 430.0 million, share ~ 14.7 %, CAGR ~ 9.5 %
• Germany: Market size ~ USD 300.0 million, share ~ 10.2 %, CAGR ~ 8.8 %
• United Kingdom: Market size ~ USD 280.0 million, share ~ 9.5 %, CAGR ~ 8.9 %
• Japan: Market size ~ USD 200.0 million, share ~ 6.8 %, CAGR ~ 8.6 %

Neurological Biomarkers Market Regional Outlook

NORTH AMERICA

North America in 2024 accounted for more than 41.6% share of the global Neurological Biomarkers Market. The United States is the dominant country, capturing around 91.0% of North America’s share in 2024. U.S. neurological biomarkers market size was about USD 2.5 billion in 2024. Alzheimer’s disease application is the largest segment in North America, contributing roughly 35.0% of the application share. Proteomic biomarkers type segment in North America held about 30‑31% share in 2024; imaging biomarkers similarly strong (~29.5% projected for 2025). Research organizations end‑user segment held ~45.0% share globally; North America hosts many leading research orgs funding discovery. Hospital laboratories end‑use share in U.S. is estimated around 36% in 2025. Independent clinical diagnostic centers also present, though lower share relative to hospital labs. North America leads in product development: leading companies (e.g. Abbott, Thermo Fisher Scientific, Bio‑Rad) have major operations in U.S. There is high prevalence: Parkinson’s disease affects around 1.0 million in U.S., Alzheimer’s around 6.7 million in 2024. Regulatory environment supports biomarker approvals. U.S. R&D funding and trials are dense; hospital labs capable of advanced imaging and proteomic assays. High healthcare infrastructure enables penetration of imaging biomarkers and less invasive proteomic tests. Therefore, North America remains the reference region in Neurological Biomarkers Market Analysis, Market Trends, Market Outlook.

North America is projected to lead with a market size of USD 3,200 million in 2025, representing ~ 35.0% share of the global market, and forecast to grow at a CAGR of 8.6 % through 2034.

North America – Major Dominant Countries

• United States: Market size ~ USD 2,750 million, share ~ 85.9 %, CAGR ~ 8.7 %
• Canada: Market size ~ USD 250 million, share ~ 7.8 %, CAGR ~ 8.4 %
• Mexico: Market size ~ USD 105 million, share ~ 3.3 %, CAGR ~ 8.1 %
• Puerto Rico: Market size ~ USD 60 million, share ~ 1.9 %, CAGR ~ 8.2 %
• Costa Rica: Market size ~ USD 35 million, share ~ 1.1 %, CAGR ~ 8.0 %

EUROPE

Europe holds a substantial portion of global Neurological Biomarkers Market, second to North America. European countries show strong adoption of imaging biomarkers (MRI, PET) and proteomic types, similar to U.S. Alzheimer’s disease is major application across Europe, with other neurodegenerative diseases like Parkinson’s and Multiple Sclerosis important especially in northern and western countries. The share for Alzheimer’s disease in application globally is ~35.0%, and in Europe this segment approximates similar levels. Research organizations across Europe account for large shares of end‑use; hospital laboratories in Germany, UK, France are well equipped. Genomic biomarkers segments in Europe approximate closely to global genomic share (~35%) in certain reports. Independent diagnostic centers in Europe are more regulated; adoption of blood‐based proteomic biomarkers in clinical diagnostics is increasing. Imaging biomarker share (~29‑30%) strong in Europe due to public health systems investing in imaging capacity. Eastern Europe, Southern Europe show rising research and clinical activity but lower infrastructure than Western Europe. Europe contributes a significant percentage to global neurology biomarker publication output. For example, several European biotech firms are active in Alzheimer’s proteomic biomarker assays; imaging tracer production for amyloid PET is robust. Europe also faces regulatory harmonization challenges among EU member states, slower reimbursement in certain countries. However, medical research funding from EU institutions supports standardized biomarker validation. Europe in many reports is projected to hold between 25‑35% of the non‑North American market share, though exact number varies. The region is also increasing partnerships between biotech companies and research organizations to develop neurological biomarker diagnostics.

Europe is estimated at USD 2,350 million in 2025, holding ~ 25.7% share, and expected to grow at a CAGR of 8.5 % through 2034.

Europe – Major Dominant Countries

• Germany: Market size ~ USD 550 million, share ~ 23.4 %, CAGR ~ 8.6 %
• United Kingdom: Market size ~ USD 420 million, share ~ 17.9 %, CAGR ~ 8.7 %
• France: Market size ~ USD 350 million, share ~ 14.9 %, CAGR ~ 8.4 %
• Italy: Market size ~ USD 280 million, share ~ 11.9 %, CAGR ~ 8.3 %
• Spain: Market size ~ USD 200 million, share ~ 8.5 %, CAGR ~ 8.5 %

ASIA-PACIFIC

Asia‑Pacific region is emerging as a key growth zone in the Neurological Biomarkers Market. Though in 2024 Asia‑Pacific holds a smaller share compared to North America and Europe, the region is showing the fastest advancement in terms of adoption of proteomic and genomic biomarkers. Countries like China, India, Japan, Australia, South Korea are increasing investments in research infrastructure. Japan holds approximate 5.3% share in Asia‑Pacific market forecasts by 2035 in certain reports. India is projected to hold about 6.1% share in Asia‑Pacific forecasts by 2035. The increasing age population in China and India, rising prevalence of Alzheimer’s and Parkinson’s, along with rising awareness and affordability of diagnostics, drive demand. Imaging biomarkers are gaining traction but cost and availability remain constraints; proteomic biomarkers (blood‑based) are being adopted more rapidly. Genomic and metabolomic biomarkers are being explored in research settings; large cohorts in China are being used. Hospital laboratories in Asia‑Pacific are expanding advanced diagnostic capabilities; independent diagnostic centers begin offering proteomic assays and mobile/digital biomarkers. Alzheimer’s application dominates Asia‑Pacific similar to global trend (≈35%), Parkinson’s and multiple sclerosis smaller but rising. Market share in Asia‑Pacific excluding Japan and Australia is growing from low base; countries like India forecast share around 6‑7% of global market by 2035. Regulatory improvements and public health initiatives are enabling early diagnosis programs. Though infrastructure gaps exist, opportunity large due to population size and unmet diagnosis needs. Therefore Asia‑Pacific figures importantly in Neurological Biomarkers Market Forecast, Market Opportunities, Market Insights.

Asia’s market is projected at USD 1,850 million in 2025, or ~ 20.2% share, with a forecast CAGR of 9.0 % through 2034.

Asia – Major Dominant Countries

• China: Market size ~ USD 600 million, share ~ 32.4 %, CAGR ~ 9.5 %
• Japan: Market size ~ USD 400 million, share ~ 21.6 %, CAGR ~ 8.5 %
• India: Market size ~ USD 250 million, share ~ 13.5 %, CAGR ~ 9.2 %
• South Korea: Market size ~ USD 200 million, share ~ 10.8 %, CAGR ~ 9.0 %
• Australia: Market size ~ USD 150 million, share ~ 8.1 %, CAGR ~ 8.8 %

MIDDLE EAST & AFRICA

Middle East & Africa currently holds smaller fraction of global Neurological Biomarkers Market compared to North America, Europe, Asia‑Pacific. Exact share in 2024 is relatively low (single digits percentage) in many reports, though growing. Countries such as Saudi Arabia, UAE, South Africa are leading in regional adoption. In those countries imaging capacity is limited, but proteomic biomarkers type adoption is increasing via imported assays. Research organizations in ME&A are initiating pilot studies; hospital laboratories in larger cities acquiring advanced diagnostic tools. Alzheimer’s disease application is still the dominant disease focus; Parkinson’s, multiple sclerosis less prevalent but rising. Genomic biomarkers usage is constrained by cost and regulatory environment; metabolomic and digital/other biomarkers are at early stages. Government support and funding in Middle East countries increasing; in Africa, international organizations are helping with clinical trials and biomarker validation. The share in ME&A of global market in 2024 is possibly low (<5‑8%), but projections indicate increasing share over forecast period. End‑user share in hospital labs in ME&A is expected to rise; research organizations are currently major end‑users in that region. Imaging biomarkers share lower due to infrastructure constraints; proteomic and blood‑based tests provide major opportunity. Regional insights show regulatory harmonization and reimbursement still challenge; however, awareness among clinicians increasing, resulting in growing demand and involvement in Neurological Biomarkers Market Industry Report, Market Analysis, Market Opportunity.

The Middle East & Africa region is estimated at USD 413.92 million in 2025, holding ~ 4.5% share, and poised to grow at a CAGR of 8.4 % through 2034.

Middle East & Africa – Major Dominant Countries

• Saudi Arabia: Market size ~ USD 110 million, share ~ 26.6 %, CAGR ~ 8.5 %
• South Africa: Market size ~ USD 85 million, share ~ 20.5 %, CAGR ~ 8.3 %
• United Arab Emirates: Market size ~ USD 70 million, share ~ 16.9 %, CAGR ~ 8.6 %
• Egypt: Market size ~ USD 65 million, share ~ 15.7 %, CAGR ~ 8.2 %
• Nigeria: Market size ~ USD 40.9 million, share ~ 9.9 %, CAGR ~ 8.4 %

List of Top Neurological Biomarkers Market Companies

• Acumen Pharmaceuticals
• Thermo Fisher Scientific Inc.
• Athena Diagnostics
• Myriad RBM
• Abbott
• Alseres Pharmaceuticals, Inc.
• BANYAN BIOMARKERS, INC.
• QIAGEN
• Bio‑Rad Laboratories, Inc.
• AbaStar MDx, Inc.

Thermo Fisher Scientific Inc. and Abbott are the two top companies with the highest market share. Thermo Fisher holds one of the leading positions as a provider of proteomic and genomic biomarker assay kits, contributing to nearly 14‑18% share in analogous brain biomarkers markets. Abbott similarly commands a significant share, being among the top 2‑3 players globally, often contributing shares in the 10‑18% range in similar segments.

Investment Analysis and Opportunities

Investment activity in the Neurological Biomarkers Market is strongly concentrated on precision diagnostics, early disease detection, and biomarker validation platforms, with over 67% of life-science companies allocating R&D budgets toward neurological biomarker development. More than 58% of global neuroscience clinical trials now incorporate at least 1 validated biomarker endpoint, improving diagnostic accuracy by 32% compared to symptom-based evaluation. Investments in genomics and proteomics platforms represent 44% of total biomarker-related capital allocation, driven by the need to analyze datasets exceeding 1 million molecular variables per patient cohort. Public–private research collaborations account for 36% of funded neurological biomarker programs, accelerating translation timelines by 28%. Diagnostic automation investments support 41% of laboratory workflows, reducing biomarker testing turnaround time by 35%. Emerging economies attract 21% of new biomarker infrastructure investments, supported by neurological disorder prevalence growth above 40%. These factors collectively expand Neurological Biomarkers Market Opportunities across research, diagnostics, and therapeutic monitoring applications.

New Product Development

New product development in the Neurological Biomarkers Market focuses on multi-analyte panels, high-sensitivity assays, and AI-enabled biomarker interpretation, with over 62% of newly launched products designed for early-stage neurodegenerative disease detection. Ultra-sensitive blood-based biomarker assays now detect protein concentrations as low as 1 picogram per milliliter, improving early diagnosis rates by 29%. Multiplex testing platforms support simultaneous analysis of 50–100 biomarkers, reducing sample volume requirements by 45%. Imaging biomarker software advancements improve lesion detection accuracy by 34%, supporting earlier intervention planning. AI-assisted data interpretation tools are embedded in 38% of new diagnostic solutions, reducing false-positive rates by 22%. Genomic biomarker kits now cover 15+ neurological gene panels, enabling personalized risk assessment for disorders such as Alzheimer’s and Parkinson’s. These innovations enhance clinical utility, scalability, and diagnostic confidence, strengthening Neurological Biomarkers Market Insights across hospital laboratories and research organizations.

Five Recent Developments (2023–2025)

• Thermo Fisher Scientific Inc. expanded neurological proteomics assay portfolios, enabling detection of 60+ brain-related protein biomarkers, improving neurodegenerative disease stratification accuracy by 31%.
• Abbott advanced blood-based neurological biomarker testing platforms, supporting early cognitive impairment screening with sensitivity levels exceeding 90% in controlled clinical environments.
• QIAGEN enhanced genomic biomarker panels covering 20+ neurological risk genes, supporting population-scale screening programs exceeding 500,000 tested samples annually.
• Bio-Rad Laboratories, Inc. launched high-throughput multiplex immunoassay systems capable of processing 1,000+ neurological samples per day, increasing laboratory productivity by 37%.
• Acumen Pharmaceuticals progressed biomarker-guided therapeutic evaluation programs, using 3 validated biomarkers to monitor disease progression and treatment response in neurodegenerative disorders.

Report Coverage of Neurological Biomarkers Market

The Neurological Biomarkers Market Report provides comprehensive coverage across 5 biomarker types and 4 application segments, analyzing diagnostic adoption across 35+ neurological disorders affecting over 1 billion individuals globally. The report evaluates biomarker utilization rates exceeding 60% in neuroscience research and 48% in clinical diagnostic settings. Coverage includes laboratory infrastructure where hospital laboratories account for 42% of biomarker testing volume, research organizations contribute 33%, and independent diagnostic centers represent 19%. Regional assessment spans 4 major regions and 30+ countries, evaluating testing accessibility, biomarker validation progress, and clinical integration levels exceeding 70% in advanced healthcare systems. Competitive analysis highlights market concentration where the top 2 companies control over 30% of global neurological biomarker testing platforms. The report further examines technology pipelines exceeding 800 active biomarker development programs, regulatory readiness indicators, and data integration capabilities shaping the Neurological Biomarkers Market Outlook, Market Insights, and long-term strategic planning for diagnostics developers, research institutions, and healthcare providers.

Neurological Biomarkers Market Report Coverage